Convergence in medicine

The future of medicine is interdisciplinary with contributions from natural sciences, social sciences and humanities. At this seminar, we showcase collaboration across disciplines in research on personalised cancer therapies; organ on a chip and nano-devices; and epigenetics and bioethics of human embryonic development. All topics with international keynote speakers.

Swipe on the arrows on the pictures in the image carousel below to see pictures and watch videos from the event.

Error: resource not found: /english/research/strategic-research-areas/life-science/oslo-life-science-2018/pictures/convergence-medicine

Main target groups: Researchers and students at UiO, OUS and Ahus.

In 2017 UiO:Life Science appointed the first convergence environments – interdisciplinary research groups that will solve grand challenges. Three of the groups are based on close collaboration between UiO and Oslo University Hospital (OUS). At this seminar you will hear short talks from different disciplines within the convergence environments. Also, each environment has invited an international speaker in the front of their research fields. 


Registration fron 12.30

13.00 Session 1

Professor Finn-Eirik Johansen, chairperson the board UiO:Life Science and vice dean research the Faculty of Mathematics and Natural Sciences, UiO


Personalised cancer therapies

Professor Trevor Graham, Barts Cancer Institute UK

Predicting cancer evolution 

Graham´s lab measures the patterns of clonal evolution that define carcinogenesis and develops novel mathematical tools for analysis and prediction. By characterising tumour evolution, his lab aims to find better ways to determine prognosis and more effective ways to treat cancers.

Three short presentations form the convergence environment
Personalised cancer therapies (PERCATHE)

The convergence environment will develop a new approach to personalised cancer therapy, based on mathematical, statistical and biological methods. It will also study the ethical, societal and regulatory perspectives.

Professor Arnoldo Frigessi, background for the convergence environment and the biostatistical perspectives.
Institute of Basic Medical Sciences, Faculty of Medicine, director of Oslo Centre for Biostatistics and Epidemiology (OCBE), UiO/OUS


Professor Kjetil Tasken, the biological perspectives
Director Centre for Molecular Medicine Norway (NCMM), the Faculty of Medicine, UiO. Head and Director of Institute for Cancer Research Oslo University Hospital (OUH) from 1 January 2018.

Åslaug Helland, the clinical perspectives
Professor II, Institute of Clinical Medicine, Faculty of Medicine, UiO

14.05 Short coffee break

14.25 Session 2

Organ on a chip and nano-devices

Dr. Peter Loskill: Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Germany

Stem cell based microphysiological Organ-on-a-Chip systems as in vitro models of human tissue

Loskill works at the borders where physics and engineering meet biology and medicine. Using human induced pluripotent stem cells (iPS cells) the aim is to develop in vitro disease-specific model tissues and organs to be used for high content drug screening and patient specific medicine. Currently his lab id interested in “heart-on-chip” and “fat-on-chip” platforms.

Three short presentations form the convergence environment
Organ on a chip and nano-devices (CHIP)

The convergence environment will develop an “Organ on a chip” interface. This will provide a powerful new platform for understanding and testing of physiological functions and therapeutic interventions.

Professor Stefan Krauss , the background for the convergence environment and the biological perspectives,
Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, UiO, and Oslo University Hospital (OUS)

Professor Ørjan Grøttem Martinsen, the electronics perspective:
Linear and non-linear electrical properties of biomaterials

Dr. Hanne Scholtz, the clinical perspectives
Division of surgery, inflammatory medicine and transplantation, OUS

Epigenetics and bioethics of human embryonic development

Professor Mary Herbert, Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, UK

Preventing germline transmission of mitochondrial DNA mutations – therapeutic potential and ethical considerations

Herbert leads a team of clinical and research scientists working side by side in a programme of basic, translational and clinical science. The aim is to improve the treatment and understanding of infertility and extending the scope of reproductive technologies to prevent transmission of disease. She has developed a groundbreaking technique to transfer healthy mitochondria to fertilized embryos.

Three short presentations from the convergence environment
Epigenetics and bioethics of human embryonic development

The convergence environment wants to understand the epigenetic reprogramming of early embryo development and its significance for human reproduction both scientifically and ethically. An overarching theme will be the understanding of epigenetic information in the passing of life from one generation of humans to the next.

Professor II Arne Klungland, background for the convergence environment and the biological perspectives
Institute of Basic Medical Sciences, Faculty of Medicine, UiO, and Clinic for Laboratory Medicine (KLM), Oslo University Hospital (OUS)


Associate Professor, Anna Smajor, the ethical perspectives
Department of Philosophy, Classics, History of Art and Ideas, Faculty of Humanities, UiO

Professor II, Péter Fedorcsák,the clinical perspectives
Institute of Clinical Medicine, Faculty of Medicine, UiO, and Department of Reproductive Medicine, OUS

16.15–17.00 Refreshments and mingling


Published June 23, 2017 12:54 PM - Last modified Nov. 20, 2019 7:33 AM